C

Clinilabs Drug Development Corporation | Eatontown, NJ

Research site

(Unclaimed)

Location

4 Industrial Way West 2nd Floor, Eatontown, New Jersey, United States of America

Site insights

Top conditions

Top treatments

INZ-701

GATE-101

CYB003

ANC-501

Psilocybin Analog

Heroin

OXY

IXT-m200

Parent organization

This site is a part of Clinilabs Drug Development Corporation

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 13 total trials

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Defici...

Enrolling

Arterial Calcification

Autosomal Recessive Hypophosphatemic Rickets Type 2

Drug: INZ-701

An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia (Jive)

This is an open-label extension (OLE) study designed to evaluate the long-term safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), an...

Invitation-only

Friedreich Ataxia

Biological: CTI-1601

ANC-501 in the Treatment of Adults With Major Depressive Disorder

This is a single-arm, open-label Phase 2 study to assess the safety, tolerability, pharmacokinetics (PK), and activity of ANC-501 oral capsules as ad...

Active, not recruiting

Major Depressive Disorder

Drug: ANC-501

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-...

Active, not recruiting

Autosomal Recessive Hypophosphatemic Rickets

Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

Drug: INZ-701